OnabotulinumtoxinA in the treatment of neurogenic bladder

Biologics: Targets and Therapy

Volumn 6, Issue , 2012, Pages 299-306

  Gulamhusein, Aziz ^a   Mangera, Altaf ^a  

^a ROYAL HALLAMSHIRE HOSPITAL   (United Kingdom)

Author keywords

Botulinum toxin; Detrusor sphincter dyssynergi; Neurogenic bladder; Neurogenic detrusor overactivity; Onabotulinumtoxina

Indexed keywords

BOTULINUM TOXIN; BOTULINUM TOXIN A; BOTULINUM TOXIN B; MUSCARINIC RECEPTOR BLOCKING AGENT; PLACEBO; RESINIFERATOXIN;

ADVERSE OUTCOME; BLADDER CATHETERIZATION; DETRUSOR DYSSYNERGIA; DOSE RESPONSE; DRUG CLASSIFICATION; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG USE; ELECTROSTIMULATION; HEMATURIA; HUMAN; INFECTION; LOW DRUG DOSE; LOWER URINARY TRACT SYMPTOM; MAGNETIC STIMULATION; MUSCLE WEAKNESS; NEUROGENIC BLADDER; OVERACTIVE BLADDER; PATIENT SELECTION; QUALITY OF LIFE; REVIEW; URGE INCONTINENCE; URINARY TRACT INFECTION; URINARY URGENCY; VESICOURETERAL REFLUX;

EID: 84866758921     PISSN: 11775475     EISSN: 11775491     Source Type: Journal    
DOI: 10.2147/BTT.S30180     Document Type: Review

References (58)

1. Gerridzen RG, Thijssen AM, Dehoux E. Risk factors for upper tract deterioration in chronic spinal cord injury patients. J Urol. 1992;147(2): 416-418.
2. Burns AS, Rivas DA, Ditunno JF. The management of neurogenic bladder and sexual dysfunction after spinal cord injury. Spine (Phila Pa). 1976;26(Suppl 24):S129-S136.
3. Hackler RH. A 25-year prospective mortality study in the spinal cord injured patient: comparison with the long-term living paraplegic. J Urol. 1977;117(4):486-488.
4. Lidal IB, Snekkevik H, Aamodt G, Hjeltnes N, Biering-Sorensen F, Stanghelle JK. Mortality after spinal cord injury in Norway. J Rehabil Med. 2007;39(2):145-151.
5. Pannek J, Stohrer M, Blok B, et al. Guidelines on Neurogenic Lower Urinary Tract Dysfunction. Arnhem, The Netherlands: European Association of Urology; 2011.
6. Marrie RA, Cutter G, Tyry T, Vollmer T, Campagnolo D. Disparities in the management of multiple sclerosis-related bladder symptoms. Neurology. 2007;68(23):1971-1978.
7. Satar N, Bauer SB, Shefner J, Kelly MD, Darbey MM. The effects of delayed diagnosis and treatment in patients with an occult spinal dysraphism. J Urol. 1995;154(2 Pt 2):754-758.
8. Madersbacher H. The various types of neurogenic bladder dysfunction: an update of current therapeutic concepts. Paraplegia. 1990;28(4): 217-229.
9. Rickwood AM. Assessment and conservative management of the neuropathic bladder. Semin Pediatr Surg. 2002;11(2):108-119.
10. Madhuvrata P, Singh M, Hasafa Z, Abdel-Fattah M. Anticholinergic drugs for adult neurogenic detrusor overactivity: a systematic review and meta-analysis. Eur Urol. February 25, 2012. [Epub ahead of print.]
11. Chancellor MB, Anderson RU, Boone TB. Pharmacotherapy for neurogenic detrusor overactivity. Am J Phys Med Rehabil. 2006;85(6): 536-545.
12. Stohrer M, Pannek J. Surgery to improve reservoir function. In: Corcos J, Schick E, editors. Textbook of the Neuropathic Bladder. 2nd ed. London, UK: Informa Healthcare; 2008.
13. Linsenmeyer TA, Horton J, Benevento J. Impact of alpha1-blockers in men with spinal cord injury and upper tract stasis. J Spinal Cord Med. 2002;25(2):124-128.
14. Talbot HS, Mahoney EM, Jaffee SR. The effects of prolonged urethral catheterization. I. Persistence of normal renal structure and function. J Urol. 1959;81(1):138-145.
15. McClurg D, Ashe RG, Marshall K, Lowe-Strong AS. Comparison of pelvic floor muscle training, electromyography biofeedback, and neuromuscular electrical stimulation for bladder dysfunction in people with multiple sclerosis: a randomized pilot study. Neurourol Urodyn. 2006;25(4):337-348.
16. Greenwell TJ, Venn SN, Mundy AR. Augmentation cystoplasty. BJU Int. 2001;88(6):511-525.
17. Khastgir J, Hamid R, Arya M, Shah N, Shah PJ. Surgical and patient reported outcomes of 'clam' augmentation ileocystoplasty in spinal cord injured patients. Eur Urol. 2003;43(3):263-269.
18. Schmidt RA, Tanagho EA. Feasibility of controlled micturition through electric stimulation. Urol Int. 1979;34(3):199-230.
19. Chaabane W, Guillotreau J, Castel-Lacanal E, et al. Sacral neuromodulation for treating neurogenic bladder dysfunction: clinical and urodynamic study. Neurourol Urodyn. 2011;30(4):547-550.
20. Bennett JK, Green BG, Foote JE, Gray M. Collagen injections for intrinsic sphincter deficiency in the neuropathic urethra. Paraplegia. 1995;33(12):697-700.
21. Chartier KE, Genevois S, Game X, et al. Treatment of neurogenic male urinary incontinence related to intrinsic sphincter insufficiency with an artificial urinary sphincter: a French retrospective multicentre study. BJU Int. 2011;107(3):426-432.
22. Reynard JM, Vass J, Sullivan ME, Mamas M. Sphincterotomy and the treatment of detrusor-sphincter dyssynergia: current status, future prospects. Spinal Cord. 2003;41(1):1-11.
23. Pistolesi D, Selli C, Rossi B, Stampacchia G. Botulinum toxin type B for type A resistant bladder spasticity. J Urol. 2004;171(2 Pt 1): 802-803.
24. Dykstra DD, Sidi AA, Scott AB, Pagel JM, Goldish GD. Effects of botulinum A toxin on detrusor-sphincter dyssynergia in spinal cord injury patients. J Urol. 1988;139(5):919-922.
25. Schurch B, Schmid DM, Stohrer M. Treatment of neurogenic incontinence with botulinum toxin A. N Engl J Med. 2000;342(9):665.
26. Kuo HC. Urodynamic evidence of effectiveness of botulinum A toxin injection in treatment of detrusor overactivity refractory to anticholinergic agents. Urology. 2004;63(5):868-872.
27. Maria G, Brisinda G, Civello IM, Bentivoglio AR, Sganga G, Albanese A. Relief by botulinum toxin of voiding dysfunction due to benign prostatic hyperplasia: results of a randomized, placebo-controlled study. Urology. 2003;62(2):259-264.
28. Montecucco C, Molgo J. Botulinal neurotoxins: revival of an old killer. Curr Opin Pharmacol. 2005;5(3):274-279.
29. Apostolidis A, Popat R, Yiangou Y, et al. Decreased sensory receptors P2X3 and TRPV1 in suburothelial nerve fibers following intradetrusor injections of botulinum toxin for human detrusor overactivity. J Urol. 2005;174(3):977-982.
30. Lawrence GW, Aoki KR, Dolly JO. Excitatory cholinergic and purinergic signaling in bladder are equally susceptible to botulinum neurotoxin a consistent with co-release of transmitters from efferent fibers. J Pharmacol Exp Ther. 2010;334(3):1080-1086.
31. Mangera A, Andersson KE, Apostolidis A, et al. Contemporary management of lower urinary tract disease with botulinum toxin A: a systematic review of botox (onabotulinumtoxinA) and dysport (abobotulinumtoxinA). Eur Urol. 2011;60(4):784-795.
32. Reitz A, Stohrer M, Kramer G, et al. European experience of 200 cases treated with botulinum-A toxin injections into the detrusor muscle for urinary incontinence due to neurogenic detrusor overactivity. Eur Urol. 2004;45(4):510-515.
33. Giannantoni A, Di Stasi SM, Stephen RL, Bini V, Costantini E, Porena M. Intravesical resiniferatoxin versus botulinum-A toxin injections for neurogenic detrusor overactivity: a prospective randomized study. J Urol. 2004;172(1):240-243.
34. Schurch B, de Sèze M, Denys P, et al; Botox Detrusor Hyperreflexia Study Team. Botulinum toxin type A is a safe and effective treatment for neurogenic urinary incontinence: results of a single treatment, randomized, placebo controlled 6-month study. J Urol. 2005;174(1): 196-200.
35. Schurch B, Denys P, Kozma CM, Reese PR, Slaton T, Barron RL. Botulinum toxin A improves the quality of life of patients with neurogenic urinary incontinence. Eur Urol. 2007;52(3):850-858.
36. Cruz F, Herschorn S, Aliotta P, et al. Efficacy and safety of onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity: a randomised, double-blind, placebo-controlled trial. Eur Urol. 2011;60(4):742-750.
37. Ginsberg D, Gousse A, Keppenne V, et al. Phase 3 efficacy and safety study of onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity. [Abstract]. Presented at the 2011 Annual Meeting of the American Urological Association, May 14-19, 2011, Washington, DC.
38. Herschorn S, Gajewski J, Ethans K, et al. Efficacy of botulinum toxin A injection for neurogenic detrusor overactivity and urinary incontinence: a randomized, double-blind trial. J Urol. 2011;185(6):2229-2235.
39. Apostolidis A, Mourad S, Thompson C, Yan X, Haag-Molkenteller C. A dose-exploration study of the efficacy and safety of onabotulinumtoxina in patients with urinary incontinence due to neurogenic detrusor overactivity. International Continence Society meeting, August 29-September 2, 2011, Glasgow, Scotland.
40. Abdel-Meguid TA. Botulinum toxin-A injections into neurogenic overactive bladder - to include or exclude the trigone? A prospective, randomized, controlled trial. J Urol. 2010;184(6):2423-2428.
41. de Sèze M, Petit H, Gallien P, et al. Botulinum a toxin and detrusor sphincter dyssynergia: a double-blind lidocaine-controlled study in 13 patients with spinal cord disease. Eur Urol. 2002;42(1):56-62.
42. Gallien P, Reymann JM, Amarenco G, Nicolas B, de Sèze M, Bellissant E. Placebo controlled, randomised, double blind study of the effects of botulinum A toxin on detrusor sphincter dyssynergia in multiple sclerosis patients. J Neurol Neurosurg Psychiatry. 2005;76(12):1670-1676.
43. Kuo HC. Satisfaction with urethral injection of botulinum toxin A for detrusor sphincter dyssynergia in patients with spinal cord lesion. Neurourol Urodyn. 2008;27(8):793-796.
44. Wyndaele JJ, Van Dromme SA. Muscular weakness as side effect of botulinum toxin injection for neurogenic detrusor overactivity. Spinal Cord. 2002;40(11):599-600.
45. De Laet K, Wyndaele JJ. Adverse events after botulinum A toxin injection for neurogenic voiding disorders. Spinal Cord. 2005;43(7):397-399.
46. Pannek J, Gocking K, Bersch U. Long-term effects of repeated intradetrusor botulinum neurotoxin A injections on detrusor function in patients with neurogenic bladder dysfunction. BJU Int. 2009;104(9): 1246-1250.
47. Kalsi V, Gonzales G, Popat R, et al. Botulinum injections for the treatment of bladder symptoms of multiple sclerosis. Ann Neurol. 2007; 62(5):452-457.
48. Bauer RM, Gratzke C, Roosen A, et al. Patient-reported side effects of intradetrusor botulinum toxin type A for idiopathic overactive bladder syndrome. Urol Int. 2011;86(1):68-72.
49. Stoehrer M, Wolff A, Kramer G, et al. Treatment of neurogenic detrusor overactivity with botulinum toxin A: the first seven years. Urol Int. 2009;83(4):379-385.
50. Whiteneck G, Meade MA, Dijkers M, Tate DG, Bushnik T, Forchheimer MB. Environmental factors and their role in participation and life satisfaction after spinal cord injury. Arch Phys Med Rehabil. 2004;85(11):1793-1803.
51. Khan S, Game X, Kalsi V, et al. Long-term effect on quality of life of repeat detrusor injections of botulinum neurotoxin-A for detrusor overactivity in patients with multiple sclerosis. J Urol. 2011;185(4): 1344-1349.
52. Sahai A, Khan MS, Le Gall N, Dasgupta P; GKT Botulinum Study Group. Urodynamic assessment of poor responders after botulinum toxin-A treatment for overactive bladder. Urology. 2008;71(3):455-459.
53. Comperat E, Reitz A, Delcourt A, Capron F, Denys P, Chartier-Kastler E. Histologic features in the urinary bladder wall affected from neurogenic overactivity - a comparison of inflammation, oedema and fibrosis with and without injection of botulinum toxin type A. Eur Urol. 2006;50(5): 1058-1064.
54. Apostolidis A, Jacques TS, Freeman A, et al. Histological changes in the urothelium and suburothelium of human overactive bladder following intradetrusor injections of botulinum neurotoxin type A for the treatment of neurogenic or idiopathic detrusor overactivity. Eur Urol. 2008;53(6):1245-1253.
55. Schulte-Baukloh H, Bigalke H, Miller K, et al. Botulinum neurotoxin type A in urology: antibodies as a cause of therapy failure. Int J Urol. 2008;15(5):407-415.
56. Pistolesi D, Giannarini G, Stampacchia G, Selli C. Should we stop using botulinum neurotoxin type a in patients with neurogenic detrusor overactivity after development of secondary resistance? Eur Urol. 2011;60(4):872-873.
57. Del Popolo G, Filocamo MT, Li Marzi V, et al. Neurogenic detrusor overactivity treated with English botulinum toxin a: 8-year experience of one single centre. Eur Urol. 2008;53(5):1013-1019.
58. Sahai A, Dowson C, Khan MS, Dasgupta P. Repeated injections of botulinum toxin-A for idiopathic detrusor overactivity. Urology. 2010; 75(3):552-558.